Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) – Analysts at Erste Group Bank raised their FY2026 earnings estimates for Thermo Fisher Scientific in a research report issued on Monday, July 27th. Erste Group Bank analyst H. Engel now expects that the medical research company will post earnings per share of $25.12 for the year, up from their prior forecast of $24.85. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $25.12 per share. Erste Group Bank also issued estimates for Thermo Fisher Scientific’s FY2027 earnings at $27.43 EPS.
Several other equities analysts have also recently weighed in on the company. Stifel Nicolaus cut their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, April 24th. Wolfe Research began coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target on the stock. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Royal Bank Of Canada boosted their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. Finally, Piper Sandler increased their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $617.14.
Thermo Fisher Scientific Stock Up 0.2%
TMO stock opened at $577.38 on Thursday. The stock has a market capitalization of $214.56 billion, a price-to-earnings ratio of 31.06, a price-to-earnings-growth ratio of 2.35 and a beta of 0.87. The company has a 50-day moving average of $501.43 and a two-hundred day moving average of $511.85. Thermo Fisher Scientific has a 52-week low of $435.27 and a 52-week high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS.
Thermo Fisher Scientific Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.
Insider Activity at Thermo Fisher Scientific
In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the transaction, the chief operating officer directly owned 24,651 shares in the company, valued at approximately $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.
Hedge Funds Weigh In On Thermo Fisher Scientific
A number of hedge funds have recently made changes to their positions in the business. Merit Financial Group LLC lifted its holdings in shares of Thermo Fisher Scientific by 47.9% during the 2nd quarter. Merit Financial Group LLC now owns 21,997 shares of the medical research company’s stock worth $11,028,000 after acquiring an additional 7,125 shares during the period. Diversified Trust Co. increased its stake in Thermo Fisher Scientific by 71.1% in the second quarter. Diversified Trust Co. now owns 17,214 shares of the medical research company’s stock valued at $8,630,000 after acquiring an additional 7,155 shares during the period. Cary Street Partners Financial LLC raised its position in Thermo Fisher Scientific by 3.3% in the second quarter. Cary Street Partners Financial LLC now owns 33,339 shares of the medical research company’s stock worth $16,715,000 after purchasing an additional 1,056 shares in the last quarter. Liberty Capital Management Inc. acquired a new stake in Thermo Fisher Scientific during the second quarter valued at approximately $8,524,000. Finally, Baker Tilly Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 43.3% in the 2nd quarter. Baker Tilly Wealth Management LLC now owns 1,456 shares of the medical research company’s stock valued at $730,000 after purchasing an additional 440 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.
Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- Circle’s IBM Patent Deal Could Redraw the Stablecoin Infrastructure Race
- Survey Reveals: 62% of US Households Are Cutting Back on Protein as Grocery Prices Rise [2026]
- UnitedHealth Just Gave Wall Street a Clearer Turnaround Signal
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
